Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (16856)	5/11/2004 12:08:25 AM
From: Bluegreen	Read Replies (3) \| Respond to of 17367

Bob, we are SUPPOSED to be talking about possible HUNDREDS of THOUSANDS of people with moderate to severe psoriasis that currently walk in on their own for treatment at their local derm. THAT is the MEAT and POTATOES. What YOU and other shareholders(or should I say BAGHOLDERS???) have to worry about is the possibility of Enbrel getting the MEAT and Raptiva getting the SMALL POTATOES!!!!!! You don't recoup your SG&A expenses not to mention cost getting the biologic on the market in the first place from POSSIBLE ESOTERIC University EMERGENCY treatment of the MOST SEVERE FORMS OF PSORIASIS. NOW for the big BOO!!!! WHAT IF RAPTIVA DOESN'T GET APPROVAL IN EUROPE????? BTW, REPAIR is an UGLY word just like CURE in BIOTECH AND BIG PHARMA.........REPEAT customer is the big show. One last thing, WHO is testing Raptiva for other things.....Xoma or Genentech????.......AND is it now downgraded like Neuprex to "probe studies"????????? Isn't the competition story kind of lame at best for an excuse NOT to tell everyone the FULL STATUS and COMPLETE testing of Raptiva????? Why won't they say AT LEAST SPECIFICALLY how MANY things and WHEN it is ACTIVELY being tested????? Now asking HOW MANY SPECIFICALLY AND WHEN has NOTHING to do with competition. Funny how no one even DARES to ask these types of questions much less demanding the Neuprex Crohn's results.LOL

To: Robert K. who wrote (16856)	5/14/2004 11:19:22 AM
From: Bluegreen	Respond to of 17367

Bob, WHAT IF RAPTIVA DOESN'T GET EUROPEAN APPROVAL????? What will the stock price be IF RAPTIVA DOESN'T GET EUROPEAN APPROVAL???? What IF Raptiva sales are anemic here in the USA?????? WHY did Baxter dump Neuprex????? WHY isn't Neuprex talked about as much as it was????? HOW MUCH is the acne stuff going to COST IF it gets to market and what about possible COMPETITION from MICROLOGIX????? WHAT if CHIRON BACKS out on XOMA like Baxter did not long ago?????? Does 4 dollars look like a GOOD exit point considering ALL THE RISKS in this STOCK???? And before I forget to thank SCANNON for the epiphany...........THANK YOU SCANNON FOR SHOWING THE WAY ON FLIPPING ALL THOSE OPTIONS........IT WAS A GREAT MESSAGE TO SEND TO SHAREHOLDERS(OOPS, OR SHOULD I SAY BAGHOLDERS????)LOL!!!!!!!!!!!